Capsule Summary Slidesets

Share

Program Content

Activities

  • Liso-cel in R/R MCL
    TRANSCEND NHL 001: R/R MCL Cohort of Phase I Study of Lisocabtagene Maraleucel
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 08, 2020

  • Parsaclisib in R/R MZL
    CITADEL-204 Phase II Trial of Parsaclisib, a PI3Kδ Inhibitor, in Relapsed/Refractory Marginal Zone Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 08, 2020

    Expires: December 07, 2021

  • Liso-cel/Ibrut in CLL/SLL
    TRANSCEND CLL 004: Phase I Results With Lisocabtagene Maraleucel + Ibrutinib in Relapsed/Refractory CLL/SLL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 09, 2020

    Expires: December 08, 2021

  • Acala in CLL: CV Events
    Pooled Analysis of Cardiovascular Events From Clinical Trials Evaluating Acalabrutinib Monotherapy in CLL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 10, 2020

    Expires: December 09, 2021

  • Odronextamab in B-NHL
    Phase I Study of Odronextamab, a Novel Bispecific Antibody Targeting CD3 and CD20, for Patients With Heavily Pretreated B-Cell NHL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 10, 2020

    Expires: December 09, 2021

  • Tazemetostat in R/R FL
    Predictors of Response to Third-Line Tazemetostat in Relapsed/Refractory Follicular Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 11, 2020

    Expires: December 10, 2021

  • Ibrut + Ven for CLL
    CAPTIVATE: Updated Results From the Phase II Trial of First-line Ibrutinib Plus Venetoclax for CLL/SLL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2020

    Expires: December 13, 2021

  • cHL: Initial BV for Older Pts
    SGN35-015: Phase II Study of Frontline Brentuximab Vedotin ± Second Agent for Older Patients With cHL Ineligible for Standard CT
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2020

    Expires: December 13, 2021

  • Phase Ib ACE-CL-003 Trial
    Phase Ib ACE-CL-003: Acalabrutinib Combined With Venetoclax and Obinutuzumab or Rituximab in Treatment-Naive or Relapsed/Refractory CLL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2020

    Expires: December 14, 2021

  • Mosunetuzumab in R/R FL
    Phase I Trial of Mosunetuzumab Bispecific Antibody in Multiply Relapsed Follicular Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2020

    Expires: December 14, 2021

  • Phase I/II BRUIN Trial
    Phase I/II BRUIN Trial of LOXO-305 in Previously Treated Patients With CLL/SLL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2020

    Expires: December 16, 2021

  • VenR for R/R CLL: 5-Yr FU
    MURANO 5-Yr Analysis: Fixed-Duration Venetoclax + Rituximab vs Bendamustine + Rituximab in R/R CLL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2020

    Expires: December 16, 2021

  • CLL: Umbralisib/Ublituximab
    UNITY-CLL: Phase III Trial of Umbralisib + Ublituximab vs Obinutuzumab + Chlorambucil in Patients With CLL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 18, 2020

    Expires: December 17, 2021

  • Umbralisib for R/R iNHL
    UNITY-NHL: Umbralisib Monotherapy in Patients With R/R Indolent NHL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 18, 2020

    Expires: December 17, 2021

  • ZUMA-5
    ZUMA-5: Phase II Study of Axicabtagene Ciloleucel in R/R Indolent Non-Hodgkin Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 18, 2020

    Expires: December 17, 2021

Provided by

ProCE Banner

Supporters

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology